STOCK TITAN

Pharvaris N.V. (PHVS) Stock Price, News & Analysis

PHVS NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
30 252 sessions, November 19, 2025 to November 19, 2026
Largest daily move
+21.7% close of December 3, 2025
1-year change
+29% closing prices, November 19, 2025 to November 19, 2026
1-month change
+6.3% closing prices, October 19, 2026 to November 19, 2026

Company Description

Pharvaris N.V. (Nasdaq: PHVS) is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists for people living with bradykinin-mediated angioedema. According to company disclosures, Pharvaris is advancing therapies intended to help address unmet needs in hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), with an emphasis on oral treatments that aim to prevent and treat acute angioedema attacks.

The company’s lead product candidate is deucrictibant, described as a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist that is currently in clinical development. Pharvaris is developing deucrictibant in two oral formulations: an extended-release tablet being investigated for prophylactic (preventive) treatment of angioedema attacks, and an immediate-release capsule being investigated for on-demand treatment of attacks. Company materials state that deucrictibant is being studied for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks when they occur by inhibiting bradykinin signaling through the bradykinin B2 receptor.

Pharvaris reports that deucrictibant has received orphan drug designation for the treatment of bradykinin-mediated angioedema from the U.S. Food and Drug Administration, the European Commission, and Swissmedic. The company characterizes itself as aiming to offer therapies with what it calls injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration for people with bradykinin-mediated angioedema.

Clinical development programs

Pharvaris describes itself as a late-stage company, with deucrictibant in multiple global Phase 3 programs. For hereditary angioedema (HAE), the company highlights:

  • RAPIDe-3 (on-demand HAE treatment): a pivotal global Phase 3, placebo-controlled study of orally administered deucrictibant immediate-release capsule (20 mg) for on-demand treatment of HAE attacks in adults and adolescents (12 years and older). Company announcements report that RAPIDe-3 met its primary endpoint and all secondary efficacy endpoints with statistical significance, with a median time to onset of symptom relief of 1.28 hours versus placebo and a safety profile described as well tolerated.
  • CHAPTER-3 (HAE prophylaxis): a randomized, double-blind, placebo-controlled Phase 3 study of deucrictibant extended-release tablet (40 mg) once daily for prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE. Pharvaris indicates that this dosage is the intended commercial dose and that the study is designed to evaluate long-term prophylactic use.
  • CHAPTER-4: a long-term, open-label extension study of deucrictibant extended-release tablet (40 mg/day) for prophylactic treatment of HAE attacks, intended to assess long-term safety and effectiveness.
  • CHAPTER-1 (Phase 2 HAE prophylaxis): a two-part Phase 2 study of deucrictibant for long-term prophylaxis of HAE attacks. Final data from the randomized and open-label extension portions, as summarized by the company, showed that deucrictibant was generally well tolerated for up to approximately three years and that mean HAE attack rates were reduced within the first week of treatment and remained low throughout the open-label extension.

For acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), Pharvaris is conducting the CREAATE pivotal Phase 3 study. Company descriptions state that CREAATE is a global trial evaluating deucrictibant for both prophylactic and on-demand treatment of AAE-C1INH attacks, with a design that includes a prophylactic treatment phase using the extended-release tablet and an on-demand treatment phase using the immediate-release capsule, followed by an open-label extension.

Therapeutic focus and scientific approach

Across its disclosures, Pharvaris emphasizes a focus on all types of bradykinin-mediated angioedema, including HAE with C1 inhibitor deficiency, HAE with normal C1 inhibitor, and AAE-C1INH. The company highlights bradykinin B2 receptor antagonism as a mechanism it describes as proven and effective for treatment of bradykinin-mediated angioedema, and positions deucrictibant as an oral small molecule designed to apply this mechanism in both prophylactic and on-demand settings.

Pharvaris also reports work on a kinin biomarker assay intended to measure bradykinin and related kinin peptides in plasma. According to company presentations, this assay is being clinically validated to characterize bradykinin-mediated angioedema and may help in identifying, studying, and managing bradykinin-mediated pathologies, including angioedema.

Regulatory and corporate profile

Pharvaris N.V. is incorporated in the Netherlands and identifies its principal executive office as being located in Leiden, the Netherlands, in SEC filings. The company is a foreign private issuer that files annual reports under Form 20-F and furnishes interim updates on Form 6-K under the Securities Exchange Act of 1934. Its ordinary shares trade on the Nasdaq Stock Market under the ticker symbol PHVS, and it reports consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.

Through public offerings of ordinary shares and pre-funded warrants registered on Form F-3 and Form F-3ASR, Pharvaris has raised capital to fund late-stage clinical programs, prepare for potential commercialization, and support working capital and general corporate purposes. The company also reports inclusion in the Nasdaq Biotechnology Index, reflecting that its shares meet that index’s eligibility criteria.

Pipeline positioning

Company communications describe deucrictibant as a potential option for both on-demand and prophylactic treatment of bradykinin-mediated angioedema attacks. Pharvaris states that, with positive data in Phase 2 prophylaxis and on-demand HAE studies and late-stage global trials underway, it is preparing global marketing authorization applications for the immediate-release capsule for on-demand treatment of HAE attacks and continuing pivotal development of the extended-release tablet for prevention of HAE attacks. In addition, the CREAATE program is intended to expand the potential use of deucrictibant into AAE-C1INH.

According to its own descriptions, Pharvaris’ aspiration is to provide oral therapies that combine the convenience of oral dosing with efficacy and tolerability characteristics that it associates with existing injectable therapies, in order to prevent and treat bradykinin-mediated angioedema attacks.

Stock Performance

$32.33
+2.12%
+0.67
After hoursChange vs the $31.66 closeLast updated: at
+29%
Performance 1 year

Pharvaris N.V. (PHVS) closed at $31.66 on November 19, 2026. Over the past 12 months, the price has gained 29.0%.

See what a $1,000 investment in PHVS would be worth today

Average down calculator for PHVS

PHVS Metrics & Rankings

Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Pharvaris N.V. has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, clinical trial. View all PHVS news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
557,210
Shares Sold
18
Transactions
Most Recent Transaction
Monges Viviane (Director) sold 11,969 shares @ $33.05 on September 23, 2026

Insider selling at Pharvaris N.V. over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Pharvaris N.V. reported operating income of -$203.9M in FY2025, and net income was -$206.2M. Diluted earnings per share stood at -$3.49. The company generated -$160.9M in operating cash flow.

-$206.2M
Net Income (FY2025)
-$160.9M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

H1
2027
H1 2027 Regulatory

U.S. NDA submission

Planned U.S. NDA submission for deucrictibant XR prophylaxis based on CHAPTER-3 pivotal results; filing window H1 2027.
Q1
2027
Q1 2027 Clinical

CREAATE part1 results

CREAATE part 1 Phase 3 results for acquired angioedema due in Q1 2027; will report efficacy and mean monthly attack‑rate data.
H1
2027
H1 2027 Regulatory

U.S. prevention application

Planned U.S. prevention application submission for deucrictibant expected in H1 2027; may initiate FDA review and filing acceptance.
APR
23
April 23, 2027 Regulatory

PDUFA action date

FDA decision on deucrictibant IR 20 mg for on-demand HAE (NDA accepted); PDUFA action date Apr 23, 2027.
APR
23
April 23, 2027 Regulatory

PDUFA decision

FDA PDUFA action date for the deucrictibant immediate-release NDA; potential approval decision impacting commercialization.
APR
23
April 23, 2027 Regulatory

FDA decision

FDA PDUFA decision for deucrictibant immediate‑release HAE therapy due April 23, 2027; outcome could affect U.S. approval and launch.
APR
23
April 23, 2027 Regulatory

FDA decision date

FDA target action date for Pharvaris' oral deucrictibant (20 mg) NDA for hereditary angioedema; US decision expected on 2027-04-23.

Pharvaris N.V. has 7 upcoming scheduled events. The next event, "U.S. NDA submission", is expected in H1 2027. Investors can track these dates to stay informed about potential catalysts that may affect the PHVS stock price.

Short Interest History

Last 12 Months

Short interest in Pharvaris N.V. (PHVS) currently stands at 2.5 million shares, up 3.0% from the previous reporting period, representing 5.0% of the float. Since November 2025, short interest has increased by 473.1%.

Days to Cover History

Last 12 Months

Days to cover for Pharvaris N.V. (PHVS) currently stands at 3.6 days, down 10.7% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 251%. Across the settlements charted above, it has ranged from 1.0 to 8.1 days.

PHVS Company Profile & Sector Positioning

Pharvaris N.V. (PHVS) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing PHVS often look at related companies in the same sector, including MBX Biosciences, Inc. (MBX), NewAmsterdam Pharma Company N.V. (NAMS), Celldex Therapeutics, Inc (CLDX), Beam Therapeutics Inc. (BEAM), and Palvella Therapeutics, Inc. (PVLA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PHVS's relative position within its industry.

Frequently Asked Questions

The current stock price of Pharvaris N.V. (PHVS) is $32.33 in after-hours trading as of November 19, 2026.

The market cap of Pharvaris N.V. (PHVS) is approximately $2.3B. Learn more about what market capitalization means .

The FY2025 net income of Pharvaris N.V. (PHVS) is -$206.2M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Pharvaris N.V. (PHVS) is -$3.49 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Pharvaris N.V. (PHVS) is -$160.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The operating income of Pharvaris N.V. (PHVS) is -$203.9M for FY2025, its most recent completed fiscal year. Learn about operating income.

Pharvaris N.V. is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists for bradykinin-mediated conditions. Its primary focus is on hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), with the goal of preventing and treating angioedema attacks using oral therapies.

Deucrictibant is Pharvaris’ lead product candidate, described as a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist. It is in clinical development for the prevention and on-demand treatment of bradykinin-mediated angioedema attacks, including in hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency.

For HAE, Pharvaris is developing deucrictibant in two oral formulations. The immediate-release capsule is being evaluated in RAPIDe-3, a pivotal Phase 3 study for on-demand treatment of HAE attacks. The extended-release tablet is being evaluated in CHAPTER-3, a randomized, double-blind, placebo-controlled Phase 3 study for prophylaxis against angioedema attacks in adults and adolescents with HAE, with additional long-term data collected in the CHAPTER-4 extension study.

CREAATE is a global, pivotal Phase 3 study sponsored by Pharvaris to evaluate deucrictibant for both prophylactic and on-demand treatment of acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The trial includes a prophylactic phase using deucrictibant extended-release tablet and an on-demand phase using the immediate-release capsule, followed by an open-label extension to assess long-term safety and effectiveness.

Yes. Company disclosures state that deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration, the European Commission, and Swissmedic. These designations recognize the potential of deucrictibant in a rare disease setting.

Pharvaris reports that RAPIDe-3, a pivotal global Phase 3 study of deucrictibant immediate-release capsule for on-demand treatment of HAE attacks, met its primary endpoint and all secondary efficacy endpoints with statistical significance. The primary endpoint, median time to onset of symptom relief, was 1.28 hours for deucrictibant versus more than 12 hours for placebo, and the treatment was described as well tolerated in the study.

According to company summaries, the CHAPTER-1 Phase 2 study, including its open-label extension, showed that deucrictibant was generally well tolerated for up to approximately 34 months. The mean rate of hereditary angioedema attacks was reduced within the first week of treatment and remained low throughout the open-label extension portion of the study.

Pharvaris’ ordinary shares trade on the Nasdaq Stock Market under the ticker symbol PHVS. The company is a foreign private issuer and files annual reports on Form 20-F and interim reports on Form 6-K under the Securities Exchange Act of 1934.

Pharvaris N.V. is incorporated in the Netherlands and identifies its principal executive office as being in Leiden, the Netherlands, in its SEC filings. The company prepares and reports consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.

Pharvaris states that its aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By doing so, the company aims to provide a new standard of care in bradykinin-mediated angioedema.